ProCE Banner Activity

Working With a Multidisciplinary Care Team: Considerations for Immunotherapy in Bladder Cancer

Clinical Thought

Patients with bladder cancer benefit most from a multidisciplinary approach tailored to their disease course. Read my thoughts on when and how urologists and oncologists should consider multidisciplinary patient management.

Released: May 22, 2018

Expiration: May 21, 2019

No longer available for credit.

Share

Faculty

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Pfizer, Roche, and Sanofi; has received funds for research support from Agensys, AstraZeneca, Bayer, Dendreon, Endocyte, Genentech, Innocrin, Johnson & Johnson, Lilly, MedImmune, Medivation, Merck, Millennium, Novartis, Oncogenex, Pfizer, Progenics, Roche, Sanofi, and Sotio; and has ownership interest in Bellicum and Tyme.